alexa Controlled-release SiRNA Nanoparticles For Sustained Gene Silencing
ISSN: 2161-1025

Translational Medicine
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Share This Page

Additional Info

Loading
Loading Please wait..
 

3rd International Conference on Translational Medicine
November 03-05, 2014 Las Vegas, USA

Jinjun Shi
Accepted Abstracts: Transl Med
DOI: 10.4172/2161-1025.S1.014
Abstract
RNA interference (RNAi) has shown tremendous potential in the treatment of diverse diseases including cancer. Numerous nanoparticle (NP) platforms have been developed to facilitate the safe and effective delivery of RNAi therapeutics (e.g., siRNA), which represents a major hurdle for the clinical applications of RNAi. Nevertheless, majority of these NP systems including those in the clinical trials lack the sustained siRNA release property, and thus can only induce transient gene silencing due to the short lifetime of siRNA. Herein, we present an innovative controlled-release NP platform for sustained siRNA delivery, which can be developed through self-assembly of biodegradable and biocompatible polymers and lipids. The lipid-polymer hybrid NPs show excellent knockdown efficacy at low doses of siRNA. More importantly, these NPs can control the temporal release of siRNA for long-term, sustained silencing of target gene expression. For example, obtained results demonstrate that the expression of a target protein PHB1 can be effectively inhibited for over two weeks after short-term transfection with the NPs. The NP-mediated sustained silencing of PHB1 in turn generates more effective tumor cell growth inhibition in vitro and in vivo than the lipofectamine-siRNA complexes. Furthermore, we have applied this NP platform to simultaneously deliver siRNAs against drug resistance and chemotherapeutic drugs for synergistic cancer treatment. It is expected that the lipid-polymer hybrid NP platform with the property of sustained siRNA release could be of interest in both fundamental biological research and clinical applications.
Biography
Jinjun Shi is an Assistant Professor at Harvard Medical School, and directs the laboratory for Nanoengineering and Drug Delivery at Brigham and Women?s Hospital, Boston. He has published more than 25 papers and is an inventor of over 15 issued/pending patents. Some of his nanomedicine research work has formed the foundation for the launch of two biotechnology companies?Selecta Biosciences and Koan Therapeutics; and resulted in the clinical trial of a first-in-class synthetic nanoparticle vaccine for smoking cessation. He has also received many awards, including the K99/R00 Award from National Cancer Institute and Young Investigator Award from Prostate Cancer Foundation.
image PDF   |   image HTML
 
Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri, Food, Aqua and Veterinary Science Journals

Dr. Krish

[email protected]

1-702-714-7001 Extn: 9040

Clinical and Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

[email protected]

1-702-714-7001Extn: 9042

Chemical Engineering and Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001 Extn: 9040

Earth & Environmental Sciences

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

General Science and Health care Journals

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics and Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001 Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Informatics Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Material Sciences Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Mathematics and Physics Journals

Jim Willison

[email protected]

1-702-714-7001 Extn: 9042

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001 Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

John Behannon

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001 Extn: 9042

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords